260 related articles for article (PubMed ID: 24266596)
1. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.
Martinez-Saguer I; Cicardi M; Suffritti C; Rusicke E; Aygören-Pürsün E; Stoll H; Rossmanith T; Feussner A; Kalina U; Kreuz W
Transfusion; 2014 Jun; 54(6):1552-61. PubMed ID: 24266596
[TBL] [Abstract][Full Text] [Related]
2. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
5. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study.
Martinez-Saguer I; Rusicke E; Aygören-Pürsün E; von Hentig N; Klingebiel T; Kreuz W
Transfusion; 2010 Feb; 50(2):354-60. PubMed ID: 19788511
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
9. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
10. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
Zhang Y; Tortorici MA; Pawaskar D; Pragst I; Machnig T; Hutmacher M; Zuraw B; Cicardi M; Craig T; Longhurst H; Sidhu J
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):158-165. PubMed ID: 29316335
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
[TBL] [Abstract][Full Text] [Related]
15. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.
Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Heller C; Klingebiel T
Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents.
Baker JW; Reshef A; Moldovan D; Harper JR; Relan A; Riedl MA
J Allergy Clin Immunol Pract; 2017; 5(4):1091-1097. PubMed ID: 28202404
[TBL] [Abstract][Full Text] [Related]
17. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.
Bork K
Immunotherapy; 2014; 6(5):533-51. PubMed ID: 24635050
[TBL] [Abstract][Full Text] [Related]
18. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema.
Henry Li H; Riedl M; Kashkin J
Clin Rev Allergy Immunol; 2019 Apr; 56(2):207-218. PubMed ID: 29909591
[TBL] [Abstract][Full Text] [Related]
19. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.
Craig TJ; Bewtra AK; Bahna SL; Hurewitz D; Schneider LC; Levy RJ; Moy JN; Offenberger J; Jacobson KW; Yang WH; Eidelman F; Janss G; Packer FR; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy; 2011 Dec; 66(12):1604-11. PubMed ID: 21884533
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
